SC
PTLA

Scotia Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Scotia Capital’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-8,875
Closed -$212K – 774
2019
Q4 		$212K Sell
8,875
-500
-5% -$13.8K ﹤0.01% 687
2019
Q3 		$251K Sell
9,375
-30
-0.3% -$842 ﹤0.01% 641
2019
Q2 		$255K Sell
9,405
-245
-3% -$7.68K ﹤0.01% 634
2019
Q1 		$335K Buy
+9,650
New +$278K ﹤0.01% 562

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Scotia Capital's PTLA Position: Q1 2020 in Review

Scotia Capital sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 8,875 shares — an estimated $212K sold.

Scotia Capital first reported a position in PTLA in Q1 2019 and held it in 4 quarters. The position peaked at $335K in Q1 2019. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

  • Scotia Capital reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Scotia Capital sold 8,875 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $212K.
  • Scotia Capital first reported a position in Portola Pharmaceuticals, Inc. in Q1 2019 and held it in 4 quarters.
  • Scotia Capital's Portola Pharmaceuticals, Inc. position peaked at $335K in Q1 2019.
  • 187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on Scotia Capital's 13F filing for Q1 2020, filed 15 May 2020.